Physician profile
Jon L Dusse
NPI 1558327742
$4,667.93
in general payments reported to CMS, 2019-2025
18 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $377 · 2021: $727 · 2022: $734 · 2023: $1,227 · 2024: $664 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $990.44 | 2019-2025 | Rocklatan, Simbrinza, Clareon |
| Abbvie INC. | $815.30 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Sun Pharmaceutical Industries INC. | $531.28 | 2019-2024 | Cequa, Xelpros |
| Novartis Pharmaceuticals Corporation | $434.59 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $367.61 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $325.44 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $315.41 | 2019-2021 | |
| Oyster Point Pharma, INC. | $241.73 | 2022-2024 | Tyrvaya |
| Sight Sciences, INC. | $221.05 | 2019-2025 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $188.57 | 2019-2021 | |
| Glaukos Corporation | $70.00 | 2021-2025 | Idosetr |
| Biotissue Holdings INC. | $38.15 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $30.47 | 2019-2023 | Flarex |
| Thea Pharma INC. | $24.26 | 2025 | Iyuzeh |
| Shire North American Group INC | $21.12 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $18.05 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.48 | 2019 | |
| Harrow Eye, LLC | $16.98 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Dusse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.